HRTX

Heron Therapeutics Inc

Add to Watchlist

Advanced Chart

1.810

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.875

Open

1.800

VWAP

1.83

Vol

682.34K

Mkt Cap

276.14M

Low

1.7835

Amount

1.25M

EV/EBITDA(TTM)

Total Shares

150.65M

375.21M

EV/OCF(TTM)

P/S(TTM)

2.00

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

38.08M

+5.69%

-0.010

-83.33%

39.49M

+20.35%

0.000

-100%

42.08M

+3.17%

0.010

-50%

Estimates Revision

The market is revising Upward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by 0.14% over the past three months. During the same period, the stock price has changed by -19.91%.

Revenue Estimates for FY2025

Revise Upward

+0.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-133.3%

In Past 3 Month

Stock Price

Go Down

-19.91%

In Past 3 Month

4 Analyst Rating

245.30% Upside

Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

245.30% Upside

Current: 1.810

Low

4.00

Averages

6.25

High

9.00

245.30% Upside

Current: 1.810

Low

4.00

Averages

6.25

High

9.00

H.C. Wainwright

Brandon Folkes

Buy

initiated

2025-06-09

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-06-09

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of Heron Therapeutics with a Buy rating and $6 price target. Heron is a commercial-stage biotechnology company with multiple products, across the acute care and oncology supportive care setting, the analyst tells investors in a research note. The firm says Heron is entering a "meaningful inflection phase" on Zynrelef. Despite successful branded products in the post-surgical pain market, overall branded penetration remains low, contends H.C. Wainwright.

Needham

Serge Belanger

Strong Buy

Reiterates

2025-04-11

Reason

Needham

Serge Belanger

Price Target

2025-04-11

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2025-02-28

Reason

Needham

Serge Belanger

Price Target

2025-02-28

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2024-12-04

Reason

Needham

Serge Belanger

Price Target

2024-12-04

Reiterates

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Maintains

$5 → $4

2024-11-13

Reason

Needham

Serge Belanger

Price Target

$5 → $4

2024-11-13

Maintains

Strong Buy

Reason

Needham

Serge Belanger

Strong Buy

Reiterates

2024-09-25

Reason

Needham

Serge Belanger

Price Target

2024-09-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Heron Therapeutics Inc (HRTX.O) is 205.68, compared to its 5-year average forward P/E of -3.25. For a more detailed relative valuation and DCF analysis to assess Heron Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.25

Current PE

205.68

Overvalued PE

43.93

Undervalued PE

-50.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.21

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.26

Undervalued EV/EBITDA

-10.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.14

Current PS

1.63

Overvalued PS

9.81

Undervalued PS

0.46